Main Article Content


Objective: To evaluate the hematological, cytogenetic, and molecular responses in Colombian patients with CML chronic myeloid leukemia (CML) treated with imatinib.

Methods: Two groups of patients, one with the novo diagnostic and another in state of complete cytogenetic remission were followed for 12 months with quantitative PCR evaluations every three months and with chromosomal analysis every 6 months.

Results: The group with the novo diagnosis showed 50% of complete cytogenetic remission at 12 months while the other 50% were considered to have primary resistance. Respect the molecular analysis, 10.5% of the patients reached undetectable BCR-ABL transcripts at 12 months. In the complete cytogenetic remission group, 10.6% lost the state of complete cytogenetic remission at 12 months, 50% reached undetectable BCR-ABL transcripts but 10% showed levels higher than 10%, which in our standardization was equal to no molecular response.

Conclusions: Despite having received the conventional dosages of 400 mg/day of imatinib, the cytogenetic and molecular responses obtained in our group of Colombian patients with CML, were lower than those in other international studies.

Jaime A González, Oncologos de Occidente

Oncologos de Occidente, Armenia, Colombia

Gonzalo Guevara, Instituto Colombiano de Genetica y Oncologia Molecular

Scientific Director .

Instituto Colombiano de Genetica y Oncologia Molecular

Diego E Lopera, Oncologos de Occidente

Oncologos de Occidente, Manizales, Colombia

Manuel Gonzále González, Instituto Medico de Alta Tecnologia (IMAT), Monteria, Colombia

Instituto Medico de Alta Tecnologia (IMAT), Monteria, Colombia

José D Saavedra, Clinica Vida, Medellin, Colombia

Clinica Vida, Medellin, Colombia

José Fernando Lobaton, Hospital Militar Central, Bogota, Colombia

Hospital Militar Central, Bogota, Colombia

Jorge Enrique Duque, Oncologos Asociados de Imbanaco, Cali, Colombia

Oncologos Asociados de Imbanaco, Cali, Colombia

Druker B, Guilhot F, O’Brien S. Five- year follow-up of Imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med. 2006; 355: 2408-17. DOI:

Amer Zeidan, ES, Wang S, Wetzler Meir. What Is Imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response. Clin Adv Hematol Oncol. 2008; 6: 673-83.

Kantarjian HM, Giles FJ, O’Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am. 1998; 12: 31-80. DOI:

Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243: 290–3. DOI:

Baccarani M, Saglio G, Goldman J. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2006; 108: 1809-20. DOI:

Gabert J, Beillard E, Van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia a Europe Against Cancer program. Leukemia. 2003; 17: 2318–57. DOI:

Baccarani M, Pane M and Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica. 2008; 93: 161-6. DOI:

Kantarjian H, Sawyers CL, Hochhaus A. Hematologic and cytogenetic responses to Imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645-52. DOI:

Talpaz M, Silver RT, Druker BJ. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99: 1928-37. DOI:

De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26: 3358–63. DOI:

Usman M, Syed NN, Kakepoto GN, Adil SN, Khurshid M. Chronic phase chronic myeloid leukemia: response of Imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response. JAPI. 2007; 55: 103-07.

L Abraham J, Bapsy PP, Govind B, and Lokanatha A. Imatinib mesylate in newly diagnosed patients of chronic myeloid leukemia. Indian J Med. 2007; 28: 20-5. DOI:

Quintás-Cardama A, Kantarjian H, Cortes JE. Mechanisms of primary and secondary resistance toImatinib in chronic myeloid leukemia. J Cancer Control. 2009; 16: 123-31. DOI:

Zeidan A, Wang ES, Wetzler M. What Is Imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response. Clin Adv Hematol Oncol. 2008; 6: 673-83.

Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A . Contribution of ABL kinase domain mutations to Imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006; 12: 7374-9. DOI:

Khorashad JS, de Lavallade H, Apperley JF. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to Imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008; 26: 4806-13. DOI:

British Committee for Standards in Haematology. Recommendations for the Management of BCR-ABL-positive Chronic Myeloid Leukaemia. London. 2007.

Hughes TP, Kaeda J, Branford S. Frequency of major molecular responses to Imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349: 1423-32. DOI:

Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006; 20: 1925–30. DOI:

Kantarjian HM, Cortes JE, O’Brien S. Long-term survival benefit, and improved complete cytogenetic and molecular response rates with Imatinib mesylate in Philadelphia chromosomepositive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004; 104: 1979-88. DOI:

Kantarjian H, O’Brien S, Shan J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia need for new response definitions? Cancer. 2008; 112: 837-45. DOI:

Marin D, Milojkovic D, Olavarria E Khorashad JS, de Lavallade H, Reid AG. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with Imatinib whose eventual outcome is poor. Blood. 2008; 112: 4437-44. DOI:

Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with Imatinib: patterns of residual leukemia and prognostic factors for cytogenetic relapse. Leukemia. 2005; 19: 507-12. DOI:

Iacobucci I, Saglio G, Rosti G. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in Imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006; 12: 3037-42. DOI:

Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during Imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia. 2004; 18: 1340-46. DOI:

González, J. A., Guevara, G., Lopera, D. E., González, M. G., Saavedra, J. D., Lobaton, J. F., & Duque, J. E. (2012). Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia. Colombia Medica, 43(4), 267–272.


Download data is not yet available.
Received 2011-07-19
Accepted 2024-04-29
Published 2012-12-30